Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCA followed by D-MAG in elderly untreated AML
NCT06827899Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jul 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Event-free survival up to 60 months. Started Jul 2022; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06827899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827899.